Zacks Research Analysts Lower Earnings Estimates for Masimo

Masimo Co. (NASDAQ:MASI) – Research analysts at Zacks Research decreased their Q3 2025 EPS estimates for Masimo in a research report issued on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now expects that the medical equipment provider will earn $1.07 per share for the quarter, down from their previous estimate of $1.15. The consensus estimate for Masimo’s current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo’s Q1 2026 earnings at $1.09 EPS and Q2 2026 earnings at $1.17 EPS.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same period in the prior year, the company earned $0.63 EPS. Masimo’s revenue for the quarter was up 5.4% on a year-over-year basis.

Several other brokerages also recently issued reports on MASI. Piper Sandler upped their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Wells Fargo & Company upped their target price on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Finally, BTIG Research lifted their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $167.00.

Masimo Price Performance

Shares of MASI stock opened at $170.89 on Thursday. Masimo has a 52 week low of $91.60 and a 52 week high of $178.27. The stock has a market capitalization of $9.15 billion, a PE ratio of 117.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock’s fifty day moving average is $147.03 and its 200-day moving average is $129.03.

Institutional Trading of Masimo

A number of institutional investors have recently bought and sold shares of MASI. FMR LLC lifted its stake in shares of Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock valued at $900,860,000 after purchasing an additional 1,970,883 shares during the period. Thrivent Financial for Lutherans increased its holdings in Masimo by 42.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after purchasing an additional 360,497 shares during the last quarter. Point72 Asset Management L.P. boosted its holdings in Masimo by 107.8% during the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after buying an additional 351,523 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares during the last quarter. Finally, Farallon Capital Management LLC grew its position in shares of Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after buying an additional 177,914 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.